TY - JOUR
T1 - Insights into ovarian cancer care
T2 - Report from the Anzgog ovarian cancer webinar series 2020
AU - Obermair, Andreas
AU - Beale, Philip
AU - Scott, Clare L.
AU - Beshay, Victoria
AU - Kichenadasse, Ganessan
AU - Simcock, Bryony
AU - Nicklin, James
AU - Lee, Yeh Chen
AU - Cohen, Paul
AU - Meniawy, Tarek
PY - 2021/11
Y1 - 2021/11
N2 - Epithelial ovarian cancer (EOC) is among the top ten causes of cancer deaths worldwide, and is one of the most lethal gynecological malignancies in high income countries, with incidence and death rates expected to rise particularly in Asian countries where ovarian cancer is among the 5 most common cancers. Despite the plethora of randomised clinical trials investigating various systemic treatment options in EOC over the last few decades, both progression-free and overall survival have remained at approximately 16 and 40 months respectively. To date the greatest impact on treatment has been made by the use of poly (ADP-ribose) polymerase (PARP) inhibitors in women with advanced EOC and a BRCA1/2 mutation. Inhibition of PARP, the key enzyme in base excision repair, is based on synthetic lethality whereby alternative DNA repair pathways in tumor cells that are deficient in homologous recombination is blocked, rendering them unviable and leading to cell death. The Australia New Zealand Gynaecological Oncology Group (ANZGOG) is the national gynecological cancer clinical trials organization for Australia and New Zealand. ANZGOG's purpose is to improve outcomes and quality of life for women with gynecological cancer through cooperative clinical trials and undertaking multidisciplinary research into the causes, prevention and treatments of gynecological cancer. This review summarizes current ovarian cancer research and treatment approaches presented by Australian and New Zealand experts in the field at the 2020 ANZGOG webinar series entitled “Ovarian Cancer systems of Care”.
AB - Epithelial ovarian cancer (EOC) is among the top ten causes of cancer deaths worldwide, and is one of the most lethal gynecological malignancies in high income countries, with incidence and death rates expected to rise particularly in Asian countries where ovarian cancer is among the 5 most common cancers. Despite the plethora of randomised clinical trials investigating various systemic treatment options in EOC over the last few decades, both progression-free and overall survival have remained at approximately 16 and 40 months respectively. To date the greatest impact on treatment has been made by the use of poly (ADP-ribose) polymerase (PARP) inhibitors in women with advanced EOC and a BRCA1/2 mutation. Inhibition of PARP, the key enzyme in base excision repair, is based on synthetic lethality whereby alternative DNA repair pathways in tumor cells that are deficient in homologous recombination is blocked, rendering them unviable and leading to cell death. The Australia New Zealand Gynaecological Oncology Group (ANZGOG) is the national gynecological cancer clinical trials organization for Australia and New Zealand. ANZGOG's purpose is to improve outcomes and quality of life for women with gynecological cancer through cooperative clinical trials and undertaking multidisciplinary research into the causes, prevention and treatments of gynecological cancer. This review summarizes current ovarian cancer research and treatment approaches presented by Australian and New Zealand experts in the field at the 2020 ANZGOG webinar series entitled “Ovarian Cancer systems of Care”.
KW - BRCA1/2 Mutation
KW - High-Grade Serous Ovarian Cancer
KW - Homologous Recombination Deficiency
KW - Neoadjuvant Chemotherapy
KW - Ovarian Cancer
KW - PARP Inhibitors
UR - http://www.scopus.com/inward/record.url?scp=85121034759&partnerID=8YFLogxK
U2 - 10.3802/JGO.2021.32.E95
DO - 10.3802/JGO.2021.32.E95
M3 - Review article
C2 - 34708597
AN - SCOPUS:85121034759
SN - 2005-0380
VL - 32
JO - Journal of Gynecologic Oncology
JF - Journal of Gynecologic Oncology
IS - 6
M1 - e95
ER -